Resources Repository
-
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
Dynamic Simulation | Microsimulation | Mathematical Models | State-Transition | Policy/Regulation | Decision Analysis | Chronic Disease/Risk | Environmental Health | Health Systems | Business/Industry | Climate/Environment | Government/Law | Health/Medicine | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Technology Assessment | Policy/Regulation | Probability/Bayes | Infectious Diseases | Health Systems | Government/Law | Health/Medicine | Global | North America -
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Technology Assessment | Global Governance | Policy/Regulation | Health Outcomes | Evidence Synthesis | Infectious Diseases | Clinical Care | Business/Industry | Economics/Finance | Health/Medicine | Global -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Preferences/Values | Technology Assessment | Policy/Regulation | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Government/Law | Health/Medicine | Science/Technology | North America -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Preferences/Values | Policy/Regulation | Benefit-Cost Analysis | Infectious Diseases | Government/Law | North America -
ReportPublication 2010Priorities for the National Vaccine Plan
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine …
The authors examine the complexities of the vaccine enterprise, a fundamental component of preventive medicine and public health, from research and development of new vaccines to financing and reimbursement of immunization services. The current climate, socially, economically and politically, presents challenges and opportunities to the U.S. to strengthen the existing systems of developing, manufacturing, regulating, distributing, funding, and administering safe and effective vaccines for all people. The authors present recommendations for priority actions intended to…
Technology Assessment | Policy/Regulation | Evidence Synthesis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | North America -
Working PaperPublication 2018Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis
Increasing life expectancy is a major goal of many policies implemented around the world. As …
Increasing life expectancy is a major goal of many policies implemented around the world. As a result, the value of reducing mortality risk has been extensively studied and several organizations have developed recommendations for estimating these values in benefit-cost analysis. However, both the recommendations and the underlying research primarily address high-income settings, raising questions about the extent to which the results are applicable in low- and middle-income countries. The recommendations are also diverse, reflecting differing…
Preferences/Values | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Economics/Finance | Health/Medicine | Global -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Preferences/Values | Policy/Regulation | Priority Setting/Ethics | Health Outcomes | Decision Analysis | Benefit-Cost Analysis | Social Determinants | Economics/Finance | Health/Medicine | Global | Critical Thinking/Analysis -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Preferences/Values | Policy/Regulation | Costing Methods | Benefit-Cost Analysis | Chronic Disease/Risk | Mental Health | Economics/Finance | Government/Law | Health/Medicine | North America